Online citations, reference lists, and bibliographies.
← Back to Search

Theranostic Metallic Nanomedicine In Oncology: New Insights And Concerns

S. Akhter, F. Ramazani, M. Ahmad, J. Ahmad, I. Ahmad, Z. Rahman, S. Amin, F. Ahmad
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Cancer is a leading cause of mortality at global level, with recent advancements in research of anticancer drug therapy and diagnosis resulting in modest impacts on cancer therapy. Multifunctional or theranostic metallic nanoparticles gained attention in recent years as promising therapeutic paradigms, which provide attractive vehicles for diagnosis, and therapeutic delivery of diagnostic/active agents to tumor specific cells. Here, we discuss the cancer patho-physiology that acts as barrier in conventional chemotherapy and multidimensional aspects of metallic nanoparticles for effective cancer therapy, with particular focus on clinical stages. Keeping in mind the growing research in clinical application of metallic nanomedicines, toxicity and regulatory concerns related with these nanometric systems are also addressed in this review.
This paper references
10.1016/j.biomaterials.2008.07.004
Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging.
Tapan Jain (2008)
10.1093/NAR/GNH140
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle.
R. Schiffelers (2004)
10.1016/S0169-409X(99)00042-3
Possibility of active targeting to tumor tissues with liposomes.
Maruyama (1999)
10.1002/ANIE.200602866
Magnetic nanoparticles: synthesis, protection, functionalization, and application.
A. Lu (2007)
10.1021/NL050127S
Immunotargeted nanoshells for integrated cancer imaging and therapy.
C. Loo (2005)
10.1016/J.BIOMATERIALS.2007.01.043
Nanotoxicity of iron oxide nanoparticle internalization in growing neurons.
T. R. Pisanic (2007)
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
R. Brekken (2000)
10.1038/nrg963
Enzyme replacement and enhancement therapies: lessons from lysosomal disorders
R. Desnick (2002)
10.1021/AC0262210
A whole blood immunoassay using gold nanoshells.
L. R. Hirsch (2003)
10.1517/17425247.2011.561313
Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis
X. Ming (2011)
10.1016/j.tiv.2008.08.009
The effects of nanoparticles on mouse testis Leydig cells in vitro.
T. Komatsu (2008)
10.2174/1568009033481985
Tumor angiogenesis: a potential target in cancer control by phytochemicals.
R. Singh (2003)
10.1038/nbt1292
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung
P. Oh (2007)
10.1517/17425240903130585
Layered double hydroxide nanoparticles in gene and drug delivery
Katharina Ladewig (2009)
10.1021/CR030698+
Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology.
M. Daniel (2004)
MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis.
L. G. Remsen (1996)
10.1016/J.PROGSOLIDSTCHEM.2005.11.010
Magnetic nanoparticle design for medical applications
S. Mornet (2006)
10.1158/1078-0432.CCR-09-2232
Targeting the Insulin-like Growth Factor Receptor-1R Pathway for Cancer Therapy
Jiping Zha (2010)
10.1096/fj.06-6485fje
Titanium dioxide nanoparticles induce emphysema‐like lung injury in mice
H. Chen (2006)
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft.
F. Yuan (1994)
10.1038/nrc1566
Cancer nanotechnology: opportunities and challenges
M. Ferrari (2005)
10.1201/9781420008449
Nanoparticulate Drug Delivery Systems
Deepak Thassu (2007)
Locoregional cancer treatment with magnetic drug targeting.
C. Alexiou (2000)
10.1016/S0076-6879(86)32015-9
[13] Opsonins and dysopsonins: An overview
D. Absolom (1986)
10.1007/s00018-004-4153-5
Targeted polymeric micelles for delivery of poorly soluble drugs
V. Torchilin (2004)
10.2174/156800909789271495
Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
J. van der Veeken (2009)
10.1016/J.ADDR.2004.02.014
Nanoparticle and targeted systems for cancer therapy.
L. Brannon-Peppas (2004)
10.1517/17425247.2012.716824
Gold nanoparticles in theranostic oncology: current state-of-the-art
S. Akhter (2012)
10.1016/j.taap.2008.06.009
The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line.
M. J. Clift (2008)
10.1016/j.addr.2008.08.005
Active targeting schemes for nanoparticle systems in cancer therapeutics.
J. D. Byrne (2008)
10.1021/NL061025K
Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm.
T. Xia (2006)
Anti-CD20 treatments and the lymphocyte membrane: pathology for therapy.
B. Borisch (2001)
10.1021/la801138e
Controlled rupture of magnetic polyelectrolyte microcapsules for drug delivery.
S. Hu (2008)
10.1038/382607A0
A DNA-based method for rationally assembling nanoparticles into macroscopic materials
C. Mirkin (1996)
10.2174/187152006778699130
Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology.
S. Moghimi (2006)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Y. Matsumura (1986)
10.1073/pnas.2232479100
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance
L. R. Hirsch (2003)
10.1148/RADIOLOGY.148.1.6856817
Neuroblastoma: diagnostic imaging and staging.
David D. Stark (1983)
10.1148/RADIOLOGY.193.2.7972773
Pancreatic receptors: initial feasibility studies with a targeted contrast agent for MR imaging.
P. Reimer (1994)
10.1016/J.IJPHARM.2007.04.037
Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
H. Hatakeyama (2007)
Liposome disposition in vivo: effects of pre-dosing with lipsomes.
Abra Rm (1980)
10.1016/S0169-409X(97)00135-X
Theoretical considerations of RES-avoiding liposomes: Molecular mechanics and chemistry of liposome interactions.
Papisov (1998)
10.2174/156800911798073050
EphA2-dependent molecular targeting therapy for malignant tumors.
Rong Biaoxue (2011)
10.1016/0169-409X(95)00025-3
Long circulating microparticulate drug carriers
S. Stolnik (1995)
10.1021/AC052015R
Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells.
Joshua K Herr (2006)
10.2147/IJN.S596
Drug delivery and nanoparticles: Applications and hazards
W. D. de Jong (2008)
10.1002/mrm.10406
MR molecular imaging of the Her‐2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles
D. Artemov (2003)
With a ligand linked magnetic nanoparticles
S. Penadés (2004)
10.1039/b9nr00053d
Random walk of single gold nanoparticles in zebrafish embryos leading to stochastic toxic effects on embryonic developments.
Lauren M Browning (2009)
10.1517/17425247.2011.554818
Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems
P. Karmali (2011)
Disease of Immunity
R. Mitchell (2002)
10.1016/s0021-9258(19)37026-7
Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes.
A. Chonn (1992)
10.1158/0008-5472.CAN-05-4199
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
D. Kirpotin (2006)
10.1021/JA057254A
Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods.
X. Huang (2006)
10.1021/nn800072t
Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery.
M. Liong (2008)
10.1073/PNAS.0308728100
Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice.
J. LeBowitz (2004)
10.1186/1477-3155-2-3
Applications of nanoparticles in biology and medicine
OV Salata (2004)
10.1007/BF02976620
Recent progress in drug delivery systems for anticancer agents
C. Kim (2002)
10.1021/AC011127P
Development of an aggregation-based immunoassay for anti-protein A using gold nanoparticles.
N. Thanh (2002)
10.1016/S0163-7827(03)00033-X
Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties.
S. Moghimi (2003)
10.1088/0031-9155/49/18/N03
The use of gold nanoparticles to enhance radiotherapy in mice.
J. Hainfeld (2004)
10.1126/SCIENCE.277.5329.1078
Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles.
R. Elghanian (1997)
10.1016/0730-725X(93)90026-A
Liver-directed superparamagnetic iron oxide: quantitation of T2 relaxation effects.
D. Pouliquen (1993)
10.1016/S0169-409X(99)00041-1
The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs.
Nagayasu (1999)
In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
A. Gabizon (2003)
10.1016/S0378-5173(99)00447-0
Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system.
U. Gaur (2000)
10.1016/J.JMMM.2005.02.036
In vitro and in vivo investigations of targeted chemotherapy with magnetic nanoparticles
C. Alexiou (2005)
10.1021/CR0300789
Self-assembled monolayers of thiolates on metals as a form of nanotechnology.
J. Love (2005)
10.1038/nrc903
Ligand-targeted therapeutics in anticancer therapy
T. Allen (2002)
Drug targeting in magnetic resonance imaging.
R. Weissleder (1992)
10.1016/j.tiv.2013.01.005
Platinum folate nanoparticles toxicity: cancer vs. normal cells.
T. Mironava (2013)
10.1074/mcp.R400001-MCP200
Targeted Therapy in Breast Cancer
J. Ross (2004)
10.1002/ADFM.200801655
New Generation of Multifunctional Nanoparticles for Cancer Imaging and Therapy
Kyeongsoon Park (2009)
10.1539/joh.50.1
Body Distribution of Inhaled Fluorescent Magnetic Nanoparticles in the Mice
Jung-Taek Kwon (2008)
10.1016/S0065-2571(00)00013-3
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.
H. Maeda (2001)
10.1016/J.MRI.2004.01.050
MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents.
M. Funovics (2004)
Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors.
R. Campbell (2002)
10.1158/1078-0432.CCR-06-0946
Vascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors
G. R. Reddy (2006)
10.1002/cbic.200700323
Smart “Turn‐on” Magnetic Resonance Contrast Agents Based on Aptamer‐Functionalized Superparamagnetic Iron Oxide Nanoparticles
M. V. Yigit (2007)
10.1200/JCO.2006.07.0649
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
D. B. Agus (2007)
10.1016/J.IJPHARM.2006.12.002
Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
A. Cirstoiu-Hapca (2007)
10.1016/S0168-3659(01)00309-1
Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.
H. Maeda (2001)
10.1007/978-0-387-77667-5
Nanotechnology in drug delivery
M. M. Villiers (2009)
Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.
R. Pasqualini (2000)
10.2174/156800907781386605
Cancer prevention by dietary bioactive components that target the immune response.
L. Ferguson (2007)
10.1016/S0169-409X(97)00136-1
Controlling liposome blood clearance by surface-grafted polymers.
Woodle (1998)
10.1023/A:1011054123304
Recognition by Macrophages and Liver Cells of Opsonized Phospholipid Vesicles and Phospholipid Headgroups
S. Moghimi (2004)
10.1126/SCIENCE.281.5385.2013
Semiconductor nanocrystals as fluorescent biological labels.
M. Bruchez (1998)
10.1039/b917753a
Photoactivated chemotherapy (PACT): the potential of excited-state d-block metals in medicine.
N. J. Farrer (2009)
10.2174/1568009611313040002
Nanomedicines as cancer therapeutics: current status.
S. Akhter (2013)
10.1038/nbt720
Magnetic relaxation switches capable of sensing molecular interactions
J. M. Pérez (2002)
10.1093/TOXSCI/KFI256
In vitro cytotoxicity of nanoparticles in mammalian germline stem cells.
L. Braydich-Stolle (2005)
10.1016/S0009-9260(66)80052-1
Microcirculation of tumors. II. The supervascularized state of irradiated regressing tumors.
P. Rubin (1966)
10.1158/0008-5472.CAN-03-2798
Novel Nanosensors for Rapid Analysis of Telomerase Activity
J. Grimm (2004)
10.1002/(SICI)1097-0215(19980209)75:4<626::AID-IJC22>3.0.CO;2-5
Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti‐epidermal growth factor receptor antibody
Toshikazu Suwa (1998)
10.1016/S0168-3659(03)00242-6
VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies.
S. Dagar (2003)
10.1148/RADIOLOGY.193.3.7972790
Liver MR imaging with iron oxides: toward consensus and clinical practice.
R. Weissleder (1994)
10.1084/JEM.133.2.275
ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS
J. Folkman (1971)
10.1016/0014-5793(88)81372-3
Tissue specific opsonins for phagocytic cells and their different affinity for cholesterol‐rich liposomes
S. Moghimi (1988)
10.1016/J.JCONREL.2004.02.003
Folate receptor targeted biodegradable polymeric doxorubicin micelles.
H. Yoo (2004)
10.1002/JPS.2600681129
Distribution and elimination of poly(methyl-2-14C-methacrylate) nanoparticle radioactivity after injection in rats and mice.
J. Kreuter (1979)
10.1007/S10856-007-3130-6
Surface modified superparamagnetic iron oxide nanoparticles: as a new carrier for bio-magnetically targeted therapy
Sheng Liang (2007)
10.1021/BC015563U
Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles.
P. Wunderbaldinger (2002)
10.1016/S0009-2509(03)00234-3
Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases
S. Feng (2003)
10.1038/nm1101-1241
Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent
M. Zhao (2001)
10.1056/NEJMOA022749
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer.
M. Harisinghani (2003)
10.1158/1535-7163.MCT-06-0141
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
Rajni Sinha (2006)
10.1189/jlb.0205074
Nanotechnology for the biologist
S. Mcneil (2005)
10.1038/nbt994
In vivo cancer targeting and imaging with semiconductor quantum dots
X. Gao (2004)
10.1016/J.ADDR.2004.01.011
Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.
A. Gabizon (2004)
10.1016/S0142-9612(01)00267-8
Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake.
Y. Zhang (2002)
10.1007/BF00409698
Vascularization of tumors: A review
P. Shubik (2004)
10.1002/SMLL.200600009
Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery.
N. Kohler (2006)
10.1002/JPS.1063
Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes.
R. Campbell (2001)
10.1007/s11095-007-9348-7
Sheddable Coatings for Long-Circulating Nanoparticles
B. Romberg (2007)
10.1126/SCIENCE.300.5616.80
Quantum Dots Get Wet
C. Seydel (2003)
10.1126/SCIENCE.1088755
Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins
J. Nam (2003)
Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection.
S. Moghimi (1994)
10.1007/s11481-006-9032-4
Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System
J. Kingsley (2006)
10.1016/J.TIV.2005.06.034
In vitro toxicity of nanoparticles in BRL 3A rat liver cells.
S. Hussain (2005)
10.1088/0022-3727/36/13/203
TOPICAL REVIEW: Functionalisation of magnetic nanoparticles for applications in biomedicine
C. Berry (2003)
New developments in angiogenesis: a major mechanism for tumor growth and target for therapy.
A. Jones (1998)
10.1016/J.BBAMEM.2006.12.013
Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding.
N. Dos Santos (2007)
Long-circulating and target-specific nanoparticles: theory to practice.
S. Moghimi (2001)
10.1016/j.addr.2008.03.014
Multifunctional magnetic nanoparticles for targeted imaging and therapy.
J. Mccarthy (2008)
10.1016/S0168-3659(01)00339-X
Sterically stabilized polyplex: ligand-mediated activity.
M. Woodle (2001)
10.1016/S0169-409X(98)00003-9
Control of tumour vascular permeability.
Baban (1998)
10.1093/cvr/cvp332
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours.
E. Fonsatti (2010)
10.1021/BC960003U
Magnetically labeled secretin retains receptor affinity to pancreas acinar cells.
T. Shen (1996)
10.1517/17425247.1.1.7
Tumour-selective drug delivery via folate receptor-targeted liposomes
Xiaogang Pan (2004)
10.1016/j.colsurfb.2013.01.058
Synthesis and cellular compatibility of biomineralized Fe3O4 nanoparticles in tumor cells targeting peptides.
Y. Wei (2013)
Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation
A. Rahman (2007)
10.1021/ES062629T
Exposure of engineered nanoparticles to human lung epithelial cells: influence of chemical composition and catalytic activity on oxidative stress.
Ludwig K. Limbach (2007)
10.1002/MRM.1910400209
Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in Vivo by using transferrin receptor pathways
M. Kresse (1998)
10.1002/ADMA.200600385
Preparation of biocompatible magnetite nanocrystals for in vivo magnetic resonance detection of cancer
F. Hu (2006)
10.1093/emboj/19.7.1525
Identification of a peptide blocking vascular endothelial growth factor (VEGF)‐mediated angiogenesis
R. Binétruy-Tournaire (2000)
10.1016/S0169-409X(97)00131-2
Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity.
Patel (1998)
10.1016/S1359-6446(05)03698-6
Essential properties of drug-targeting delivery systems.
K. Petrák (2005)
10.1002/smll.200900126
Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes.
Hung-Jen Yen (2009)
10.1016/0006-291X(91)91869-E
Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating.
S. Moghimi (1991)
10.1016/J.JCONREL.2006.08.017
Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
T. Ishida (2006)
10.1016/0014-5793(92)81369-W
Enhanced IgG‐ and complement‐independent phagocytosis of sulfatide‐enriched human erythrocytes by human monocytes
M. V. Serra (1992)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar